CorMedix Inc. (CRMD) Investor Relations Documents

CorMedix Inc. (CRMD) investor relations documents from the company's IR site: 2 presentations, 38 press releases; latest deck 2026-05-22. Read in-app with summaries. First-party data.

View deck: CorMedix Therapeutics is a commercial pharmaceutical company with a diversified injectable portfolio, guiding 2026 revenue of $325–$345 million and EBITDA of $115–$135 million.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-06-08Press releaseU.S. COURT OF APPEALS FOR THE FEDERAL CIRCUIT AFFIRMS VICTORY FOR CORMEDIX THERAPEUTICS IN MINOCIN® PATENT LITIGATION
2026-05-22PresentationView deck
2026-05-14Press releaseCORMEDIX THERAPEUTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
2026-05-05Press releaseCORMEDIX THERAPEUTICS TO REPORT FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE ON MAY 14, 2026
2026-04-27Press releaseCORMEDIX THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE III RESPECT TRIAL ASSESSING REZZAYO® FOR THE PROPHYL
2026-04-07Press releaseCORMEDIX TO PARTICPATE IN NEEDHAM VIRTUAL HEALTHCARE CONFERENCE
2026-03-05Press releaseCORMEDIX INC. REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
2026-03-02Press releaseCORMEDIX INC. TO REPORT FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE ON MARCH 5, 2
2026-02-12Press releaseCORMEDIX TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES
2026-02-10PresentationView Deck
2026-02-02Press releaseCORMEDIX THERAPEUTICS ANNOUNCES SHARE REPURCHASE PROGRAM
2026-01-29Press releaseCORMEDIX THERAPEUTICS TO HOST IN-PERSON AND VIRTUAL ANALYST DAY IN NEW YORK ON FEBRUARY 10, 2026
2026-01-08Press releaseCORMEDIX THERAPEUTICS TO PRESENT AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
2026-01-08Press releaseCORMEDIX THERAPEUTICS ANNOUNCES LEADERSHIP AND BOARD UPDATES
2026-01-08Press releaseCORMEDIX THERAPEUTICS ANNOUNCES PRELIMINARY FOURTH QUARTER AND FULL YEAR 2025 RESULTS AND PROVIDES BUSINESS UPDATES
2025-12-18Press releaseCORMEDIX THERAPEUTICS ANNOUNCES POSITIVE DATA FROM ONGOING REAL WORLD EVIDENCE STUDY OF DEFENCATH
2025-10-23Press releaseCORMEDIX INC. RECEIVES INNOVATIVE TECHNOLOGY DESIGNATION FROM VIZIENT FOR DEFENCATH
2025-09-29Press releaseCORMEDIX ANNOUNCES COMPLETION OF ENROLLMENT IN PHASE III RESPECT CLINICAL TRIAL FOR REZZAYO
2025-09-08Press releaseCORMEDIX ANNOUNCES STRATEGIC MINORITY INVESTMENT IN TALPHERA
2025-09-02Press releaseCORMEDIX COMPLETES ACQUISITION OF MELINTA THERAPEUTICS, RAISES FINANCIAL GUIDANCE AND ANNOUNCES NEW LEADERSHIP TEAM
2025-08-07Press releaseCORMEDIX TO ACQUIRE MELINTA THERAPEUTICS, CREATING DIVERSIFIED SPECIALTY COMPANY WITH STRONG PRESENCE IN ACUTE CARE SETT
2025-06-27Press releaseCORMEDIX INC. ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK
2025-06-26Press releaseCORMEDIX INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK
2025-06-23Press releaseCORMEDIX INC. ANNOUNCES CUSTOMER IMPLEMENTATION
2025-04-02Press releaseCORMEDIX INC. TO PARTICIPATE IN THE 24th ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE
2025-03-25Press releaseCORMEDIX INC. REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
2025-03-18Press releaseCORMEDIX INC. TO REPORT FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE ON MARCH 25,
2025-01-21Press releaseCORMEDIX ANNOUNCES COLLABORATION FOR DEFENCATH PROMOTION TO THE VA AND OTHER FEDERAL FACILITIES
2025-01-07Press releaseCORMEDIX INC. ANNOUNCES PRELIMINARY FOURTH QUARTER 2024 RESULTS AND PROVIDES BUSINESS UPDATE
2024-12-19Press releaseCORMEDIX INC. ADDED TO NASDAQ BIOTECHNOLOGY INDEX
2024-11-26Press releaseCORMEDIX INC. SUPPORTS CMS POLICY UPDATES REGARDING ACCESS TO INNOVATIVE DRUG PRODUCTS
2024-11-04Press releaseCORMEDIX INC. TO PARTICIPATE IN THE TRUIST SECURITIES BIOPHARMA SYMPOSIUM
2024-10-30Press releaseCORMEDIX INC. REPORTS THIRD QUARTER AND NINE MONTH 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
2024-10-24Press releaseCORMEDIX INC. ANNOUNCES NEW DATA AT ASN KIDNEY WEEK 2024
2024-10-23Press releaseCORMEDIX INC. TO REPORT THIRD QUARTER 2024 FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE ON OCTOBER 30, 2024
2024-10-08Press releaseCorMedix Announces New Commercial Agreement with Mid-Sized Dialysis Operator
2024-09-19Press releaseCORMEDIX INC. ANNOUNCES NEW COMMERCIAL AGREEMENT
2024-09-13Press releaseCORMEDIX INC. TO PRESENT AT THE CANTOR GLOBAL HEALTHCARE CONFERENCE
2024-09-09Press releaseCORMEDIX INC. ANNOUNCES NEW COMMERCIAL AGREEMENT
2024-08-14Press releaseCorMedix Inc. Reports SECOND Quarter AND SIX MONTH 2024 Financial Results and Provides Business Update

CRMD overview · CRMD earnings · CRMD financials · CRMD KPIs · CRMD ownership · CRMD peers · CRMD filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.